Clover Health Investments Corp. (NASDAQ: CLOV) – Analysts’ Views Revised To A Positive

Clover Health Investments Corp. (NASDAQ:CLOV) price is hovering lower on Monday, August 13, dropping -2.27% below its previous close.

A look at today’s price movement shows that the recent level at last check reads $3.30, with intraday deals fluctuating between $3.0701 and $3.32. The company’s 5Y monthly beta was ticking 1.76. Taking into account the 52-week price action we note that the stock hit a 52-week high of $11.13 and 52-week low of $1.95. The stock added 35.25% on its value in the past month.

Clover Health Investments Corp., which has a market valuation of $1.49 billion, is expected to release its quarterly earnings report Nov 08, 2021. Analysts tracking CLOV have forecast the quarterly EPS to shrink by -0.21 per share this quarter, while the same analysts predict the annual EPS to hit -$0.79 for the year 2022 and up to -$0.64 for 2023. In this case, analysts estimate an annual EPS growth of 36.30% for the year and 19.00% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $814.62 million, with the likely lows of $749.14 million and highs of $864.8 million. The average estimate suggests sales growth for the quarter will likely rise by 296.60% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $3.31 billion for the company’s annual revenue in 2022. Per this projection, the revenue is forecast to grow 124.60% above that which the company brought in 2022.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give CLOV a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as Hold.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 6 analysts have assigned CLOV a recommendation rating as follows: 3 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 1 analyst(s) have tagged the Clover Health Investments Corp. (CLOV) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Hold, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that CLOV’s price is at present 12.00% off the SMA20 and 25.65% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 59.47, with weekly volatility standing at 9.71%. The indicator jumps to 6.87% when calculated based on the past 30 days. Clover Health Investments Corp. (NASDAQ:CLOV)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 0.24. Considering analysts have assigned the stock a price target range of $2.00-$7.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $3.58. Based on this estimate, we see that today’s price at last check is roughly 37.89% off the estimated low and -117.39% off the forecast high. Investors will no doubt be excited to see the share price rise to $3.00, which is the median consensus price, and at that level CLOV would be 6.83% from recent price.

An analysis of the Clover Health Investments Corp. (NASDAQ:CLOV) stock in terms of its daily trading volume indicates that the 3-month average is 8.91 million. However, this figure increases on the past 10-day timeline to an average of 10.92 million.

Current records show that the company has 476.06M in outstanding shares. The insiders’ percentage holdings are 3.10% of outstanding shares while the percentage share held by institutions stands at 26.40%. The stats also highlight that short interest as of Jul 14, 2022, stood at 36.26 million shares, which puts the short ratio at the time at 3.53. From this we can glean that short interest is 7.66% of company’s current outstanding shares. Notably, we see that shares short in July rose slightly given the previous month’s figure stood at 30.3 million. But the -11.29% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Reply

Your email address will not be published. Required fields are marked *